Pfizer BioTherapeutics Pharmaceutical Sciences, Chesterfield, MO 63017, USA.
Int J Pharm. 2012 Jul 15;431(1-2):1-11. doi: 10.1016/j.ijpharm.2012.04.040. Epub 2012 Apr 21.
Protein aggregation is one of the key challenges in the development of protein biotherapeutics. It is a critical product quality issue as well as a potential safety concern due to the increased immunogenicity potential of these aggregates. The overwhelming safety concern has led to an increased development effort and regulatory scrutiny in recent years. The main purposes of this review are to examine the literature data on the relationship between protein aggregates and immunogenicity, to highlight the linkage and existing inconsistencies/uncertainties, and to propose directions for future investigations/development.
蛋白质聚集是蛋白质生物疗法开发面临的关键挑战之一。由于这些聚集物潜在的免疫原性增加,这是一个关键的产品质量问题,也是一个潜在的安全问题。这种压倒性的安全担忧导致近年来研发工作和监管审查的增加。本篇综述的主要目的是检查文献数据中关于蛋白质聚集物和免疫原性之间的关系,突出其关联性和现有不一致/不确定性,并为未来的研究/开发提出方向。